ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO869

Genes Involved in Diabetic Nephropathy in a Greek Population of Diabetic Type 2 Patients

Session Information

Category: Diabetic Kidney Disease

  • 601 Diabetic Kidney Disease: Basic


  • Roumeliotis, Athanasios K., Achilleion Nephrology Center, Thessaloniki, Greece
  • Roumeliotis, Stefanos K., University Hospital Of Alexandroupolis, Alexandroupolis, Greece
  • Liakopoulos, Vassilios, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Kantartzi, Konstantia, Democritus University of Thrace, Alexandroupolis, Greece
  • Thodis, Ilias, Democritus University of Thrace, Alexandroupolis, Greece
  • Panagoutsos, Stylianos A., Democritus University of Thrace, Alexandroupolis, Greece

The incidence and prevalence of diabetic nephropathy (DN), the major cause of end stage renal disease in diabetic type 2 patients (DM2), are continuously rising. Important role in the pathogenesis of DN play metabolic factors, the oxidative stress (OS) pathway and the patient’s genetic substrate. Nevertheless, genome-wide association studies regarding the genetic causes of DN are few and inconclusive. The aim of our study was to find a possible genetic association between the single-nucleotide polymorphisms on the athway of OS studied and DN development.


Data from a genome-wide association study were utilized to perform a study between 102 DM2-DN (cases) and 230 DM2-non-DN (controls) diabetic type 2 patients of greek origin.


The polymorphisms that exhibited a significant correlation with DN development were 44 and the corresponding genes were 20. Some polymorphisms are probably potentially protective and others could be implicated in DN development. The genes with an odds ratio below 1, possibly exhibiting a protective role, were: SPP1 (p=0.001), CCS (p=0.019), ALOX12 (p=0.04), OXR1 (p=0.042), PRNP (p=0.049). The genes with an OR>1, possibly contributing to DN development, were: TPO (p=0.002), TTN (p=0.002), AOX1 (p=0.005), NOS3 (p=0.005), PDLIM1 (p=0.005), EPHX2 (p=0.013), GPX4 (p=0.019), TXNRD2 (p=0.019), MTL5 (p=0.033), EPX (p=0.035), GPX3 (p=0.036), IPCEF1 (p=0.041), GSTA7P (p=0.041), GPX6&5 (p=0.044), VKORC1 (p=0.047).


In our study 44 polymorphisms with their 20 genes on the oxidative stress pathway were found to be potentially associated with DN in greek DM2 patients.